New Reports From EMR Provide a Comprehensive Insight on the Potential of Dyslipidemia Drugs in Key Developed Markets
EMR's latest publications provide an exceptional tool to understand the current trends, therapeutic structure, competitive landscape and the outlook for key developed dyslipidemia drug markets till 2016.
- (1888PressRelease) September 06, 2011 - In its new series of reports on dyslipidemia, Expert Market Research, one of the world's leading providers of lifeScience market intelligence, analyses the market potential of dyslipidemia drugs in several key countries.
EMR's dyslipidemia market series includes the following reports:
• US Dyslipidemia Market Report and Forecast: 2011-2016
• UK Dyslipidemia Market Report and Forecast: 2011-2016
• France Dyslipidemia Market Report and Forecast: 2011-2016
• Germany Dyslipidemia Market Report and Forecast: 2011-2016
• Italy Dyslipidemia Market Report and Forecast: 2011-2016
• Spain Dyslipidemia Market Report and Forecast: 2011-2016
• Japan Dyslipidemia Market Report and Forecast: 2011-2016
• Canada Dyslipidemia Market Report and Forecast: 2011-2016
• Australia Dyslipidemia Market Report and Forecast: 2011-2016
Each of these reports provide a comprehensive analysis of the current and future market trends in the dyslipidemia drugs market. These reports also facilitate a deep insight into the current and future epidemiology of dyslipidemia and its market structure besides probing into the performance of various therapeutic classes, companies, molecules and brands. These reports can serve as an excellent guide for clients who are in need of an in-depth understanding of the market for dyslipidemia drugs.
Key Questions Answered in this Report:
• What is the current and future size of the dyslipidemia patient population?
• What are the current and future prevalence rates for dyslipidemia?
• What has been the historical performance of the dyslipidemia market and how will it behave in the coming years?
• Who are the leading companies in the dyslipidemia market and how will they perform in the coming years?
• What has been the historical performance of various dyslipidemia therapeutic classes and how will they behave in the coming years?
• What are the leading molecules in the dyslipidemia market and how will they behave in the coming years?
• What are the key late stage pipeline drugs and how will they perform once they are launched?
Why should you buy this Report?
• To gain an in-depth insight into the prevalence of dyslipidemia.
• To have it as a powerful tool for identifying your target patient population.
• To facilitate business decision-making based on historical, current and forecast market data for dyslipidemia drugs.
• To identify potential classes, drugs, partners and competitors so as to develop strategies for market penetration and drug development.
• To develop business strategies by looking at companies those have been the biggest winners and losers in the dyslipidemia market.
• To gain an understanding into future market events and make more informed business decisions.
Research Objectives Achieved in this Report:
Evaluating the Epidemiology of Dyslipidemia:
Key Aspects Analyzed:
• Current and future prevalence of dyslipidemia.
• Current and future size of the patient pool.
Comprehensive Situation Analysis of the dyslipidemia Market:
Classes Covered: Statins, Ion Exchange Resins, Fibrates, Other Cholesterol Triglyceride Regulators and all other Dyslipidemia drug classes
Key Aspects Analyzed:
• Historical, current and future market trends.
• Historical, current and future performance of various drugs.
• Historical, current and future performance of various companies.
• Product portfolio of various companies.
• Historical, current and future performance of various therapeutic classes.
• Projections for pipeline drugs.
Methodology & Information Sources:
To prepare this report, material was mined from both primary and secondary data sources. Primary information sources included data provided by pharmaceutical manufacturers, marketing strategists, scientists, doctors and product managers at leading pharmaceutical companies. Secondary data sources include both proprietary and public databases. These included company websites, annual reports, financial reports, 10K's, government resources, books, magazines, white papers, journals, analyst reports and access to thousands of proprietary databases.
Table of Contents
1. Research Methodology & Definitions
2. Executive Summary
3. Dyslipidemia Prevalence & Patient Population
3.1 Prevalence of Dyslipidemia
3.2 Dyslipidemia Patient Pool
3.3 Diagnosed & Drug Treated Patient Pool
4. The Dyslipidemia Drugs Market Landscape
4.1 Current Trends & Forecast
4.1.1 Current Market Trends
4.1.2 Market Forecast
4.2 Share of Various Players & Drugs
4.2.1 Current Trends
4.2.2 Market Forecast
4.3 Performance of Various Therapeutic Classes
4.3.1 Statins
4.3.1.1 Current Market Trends
4.3.1.2 Sales of Various Molecules
4.3.1.3 Sales Forecast
4.3.2 Ion Exchange Resins
4.3.2.1 Current Market Trends
4.3.2.2 Sales of Various Molecules
4.3.2.3 Sales Forecast
4.3.3 Fibrates
4.3.3.1 Current Market Trends
4.3.3.2 Sales of Various Molecules
4.3.3.3 Sales Forecast
4.3.4 Other Cholesterol Triglyceride Regulators
4.3.4.1 Current Market Trends
4.3.4.2 Sales of Various Molecules
4.3.4.3 Sales Forecast
4.3.5 Other Classes
4.3.5.1 Current Market Trends
4.3.5.2 Sales of Various Molecules
4.3.5.3 Sales Forecast
To buy the complete report or to get a free sample:
Call: +91-880-236-2536 (Asia), +1 206 204-1851 (America & Europe)
Email: sales ( @ ) expertmarketresearch dot com
To know more please visit: http://www.expertmarketresearch.com
For more information, visit: http://www.expertmarketreserach.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam